Litcius/Paper detail

The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials

Anita H. Clayton, Ellison Suthoff, Rakesh Jain, Mark Kosinski, Moshe Fridman, Kristina M. Deligiannidis, Samantha Meltzer‐Brody, Shih‐Yin Chen, Leon Gervitz, Ming‐Yi Huang, Madhukar H. Trivedi, Vijayveer Bonthapally

2024Journal of Affective Disorders14 citationsDOI

Topics & Concepts

PlaceboMajor depressive disorderInternal medicineDepression (economics)MedicineQuality of life (healthcare)Rating scaleHamilton Rating Scale for DepressionClinical trialPsychiatryClinical psychologyPsychologyMacroeconomicsAlternative medicineDevelopmental psychologyEconomicsPathologyAmygdalaNursingNeurotransmitter Receptor Influence on BehaviorAttention Deficit Hyperactivity DisorderTreatment of Major Depression
The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials | Litcius